IK1 inhibitor PA-6 is an efficient, specific inhibitor of inward rectifier current (IK1), blocks KIR2.x currents of human and mouse with IC50 of 12-15 nM.

IKK-2 inhibitor VIII is a potent and selective IKK-2 inhibitor with IC50 of 8.5 nM.

IKK2-IN-8 is a potent, selective IKK2 inhibitor with IC50 of 6 nM, displays >40-fold selectivity over IKK1 (IC50=230 nM).

IKK2-IN-9 is a potent, selective and orally active IKK2 inhibitor with IC50 of 19 nM, displays 20-fold selectivity over IKK1 (IC50=420 nM).

IM176OUT05 is a novel, and safe small molecule that improves the acquisition and maintenance of stem cell pluripotency, inhibits electron transport chain (ETC) in the A549 lung carcinoma cell line with IC50 of 3.2 uM.

Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imagabalin (PD 0332334) is a novel ligand for the α2δ subunit of the voltage-dependent calcium channel (VDCC) with some selectivity for the α2δ1 subunit over α2δ2.

Imatinib Mesylate is orally bioavailability mesylate salt of Imatinib, which is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 μM, 0.1 μM and 0.1 μM, respectively.

Imazapic is a selective herbicide for both the preand post-emergent control of some annual and perennial grasses and some broadleaf weeds

Imazaquin is an imidazolinone herbicide that effectively controls a broad spectrum of weed species, by inhibiting acetohydroxy acid synthase (AHAS)..

IMB-301 (NSC 301209) is a small molecule inhibitor that target the binding interface of the HIV-1 Vif/hA3G complex, inhibits the replication of HIV-1 in H9 cells (IC50=8.63 uM).

iMDK is a small molecule inhibitor of the growth factor Midkine (MDK) that suppresses the endogenous expression of MDK but not other growth factors such as PTN or VEGF.

Imidazole is a heterocyclic aromatic organic compound. It can be incorporated into many important biological molecules and acts as a corrosion inhibitor for industrial applications.

Imidazole-4(5)-acetic Acid Hydrochloride is a competitive antagonist at GABAC receptors.

Imipenem (MK-0787) is a broad-spectrum, semi-synthetic beta-lactam carbapenem that has broad antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains..

Imisopasem manganese (M40403) is a stable non-peptidyl mimetic of manganese superoxide MnSOD.

IMM-01 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 140 nM.

IMM-02 is a small molecule agonist of mammalian Diaphanous (mDia)-related formins that disrupts diaphanous inhibitory domain (DID) and diaphanous autoregulatory domain (DAD) interaction with IC50 of 99 nM.

IMP-1088 is a novel picomolar dual inhibitor of the human N-myristoyltransferases NMT1 and NMT2

IMTPPE (SID3712502) is a novel small molecule capable of inhibiting androgen receptor (AR) transcriptional activity (IC50=1 uM) and protein level in C4-2 prostate cancer cells.

In contrast to the estrogen receptor (ER) selectivity of (S)-equol , (R)-equol is a weaker ER agonist that binds to ERα and ERβ with Ki values of 27.4 and 15.4 nM, respectively.

INCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively.

INCB054329 is a novel potent, orally bioactive BET inhibitor that inhibits binding of BRD2, BRD3 and BRD4 to an acetylated histone H4 peptide with low nanomolar potency.

INCB057643 is a BET inhibitor that binds to the acetylated lysine recognition motifs found in the BRD of BET proteins, thereby preventing the interaction between the BET proteins and acetylated lysines on histones.

INCB086550 is an orally available, small molecule inhibitor of PD-L1 with potential immune checkpoint inhibitory and antineoplastic activities. In vitro, INCB086550 selectively and potently blocked the PD-L1/PD-1 interaction, induced PD-L1 dimerization and internalization, and induced stimulation-dependent cytokine production in primary human immune cells. In vivo, INCB086550 reduced tumor growth in CD34+ humanized mice and induced T-cell activation gene signatures, consistent with PD-L1/PD-1 pathway blockade. Preliminary data from an ongoing phase I study confirmed PD-L1/PD-1 blockade in peripheral blood cells, with increased immune activation and tumor growth control.

INCB10820 (PF-4178903) is a potent, selective, orally bioavailable dual CCR2 and CCR5 antagonist with binding IC50 of 3.0 nM and 5.3 nM, respectively.

INCB3344 is a novel, potent and selective small molecule antagonist of the mouse CCR2 receptor; inhibits the binding of CCL2 to mouse monocytes with nanomolar potency (IC50 = 10 nM).

Incensole is a diterpene originally isolated from frankincense produced by B. carterii.It inhibits degradation of inhibitor of NF-κB (IκBα) in a concentration-dependent manner in TNF-α-stimulated HeLa cells when used at concentrations ranging from 60 to 1

Indacaterol is an ultra-long-acting β-adrenoceptor agonist with pKi of 7.36.

Indacaterol(Onbrez; Arcapta) is an ultra-long-acting β-adrenoceptor agonist.

Indimitecan (LMP776, NSC 725776) is an anticancer DNA Topoisomerase I (Top1) inhibitor..

Indinavir(MK-639; L735524) is a potent and specific HIV protease inhibitor that appears to have good oral bioavailability.

Indisulam (E7070) is potent, sulfonamide, cell-cycle inhibitor that possesses antiproliferative activities, causes decrease in the S phase fraction along with G1 and/or G2 accumulation in various cancer cell lines.

Indolactam V ((-)-Indolactam V) is an indole alkaloid tumor promoter that activates protein kinase C (PKC), binds to PKC regulatory domains of mouse skin PKCη and rat brain PKCγ with Ki values of 3.4 nM and 1 uM, respectively.

Indoprofen is a non-steroidal anti-inflammatory drug, provide insight into treatments for spinal muscular atrophies.

Inflachromene (ICM) is a microglial inhibitor with anti-inflammatory effects, directly binds high mobility group protein 1 (HMGB1) and HMGB2 and reduces their cytoplasmic accumulation in microglial cells.

Ingenol 3-Angelate is a PKC(protein kinase C)activator; anti-cancer drug and an active ingredient in Euphorbia peplus.

Ingenol 5,20-Acetonide (CAS 77573-43-4)

Ingenol 5,20-Acetonide-3-O-angelate (CAS 87980-68-5)

Ingenol-3,4:5,20-diacetonide (CAS 77573-44-5)

inh-02 (RNF5 inhibitor inh-02) is a novel small molecule inhibitor of E3 ubiquitin ligase RNF5/RMA1.

INH1 is a cell-permeable Hec1 inhibitor, which specifically disrupts the Hec1/Nek2 interaction.

INH154 is a highly potent inhibitor for Nek2 and Hec1 binding (INH), with IC50s of 200 nM and 120 nM for INH in Hela and MB468 cells.

Inh2-B1 (STK1 inhibitor B1) is a novel specific S aureus Ser/Thr protein kinase (STK1) inhibitor with IC50 of 49 uM, directly binds to ATP-binding catalytic domain.

Inhibitor of histone deacetylase (HDAC); potently inhibits affinity purified HDAC1. Also inhibits the growth of tumor cells in vitro and in vivo. Induces p21/WAF1 expression in tumor cells.

Inhibits TNF-α processing. Also a general matrix metalloprotease and TACE inhibitor.

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.

INK055 is a dual PI3Kg/d inhibitor.

INO-1001 is a potent, selective poly(ADP-ribose) polymerase (PARP) with IC50 of <50 nM in CHO cells.

iNOS inhibitor 12 is a potent, highly selective iNOS inhibitor with IC50 of 79 nM, dispalys almost 100-fold selectivity over eNOS and nNOS..

Insulin levels modulator could be used to treat diabetes.

INT-767 is a potent, selective, dual farnesoid X receptor (FXR) and TGR5 agonist with EC50 of 30 and 630 nM, respectively.

Interferon receptor agonist is an interferonm (IFN) receptor agonist.

INX-08189 is a phosphoramidate prodrug of O-6-methyl-2-C-methyl guanosine, potent inhibitor of HCV NS5B polymerase with IC50 of 10 nM in replicon assay.

Iodipamide is a tri-iodinated benzoate derivative and ionic dimeric contrast agent used in diagnostic imaging.

Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus, used in research to raise the intracellular level of calcium (Ca2+) and as a research tool to understand Ca2+ transport across biological membranes.

Ionomycin is an ionophore produced by the bacterium Streptomyces conglobatus.

Iopamidol is a nonionic, low-osmolar iodinated contrast agent.

iOWH032 is a novel and potent CFTR inhibitor (IC50=1.01 uM) in T84 and CHO-CFTR cell based assays.

IP6K1 inhibitor TNP is a potent, selective inositol hexakisphosphate kinase IP6K with IC50 of 0.47 uM (IP6K1), does not inhibit either human or yeast Vip/PPIP5K.

IPA-3 is a selective non-ATP competitive PAK1 inhibitor with IC50 of 2.5 μM, no inhibition to group II PAKs (PAKs 4-6).

IPI-9119 (IPI9119) is a potent, selective, and irreversible inhibitor of fatty acid synthase (FASN) with IC50 of 0.3 nM in biochemical assays.

Ipidacrine hydrochloride hydrate is a reversible acetylcholinesterase (AChE) inhibitor that directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels.

Ipidacrine hydrochloride is a reversible acetylcholinesterase (AChE) inhibitor that directly stimulates impulse transmission in the central nervous system and neuromuscular synapses by blocking membrane potassium channels.

Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

IQM-266 (IQM266) is a DREAM (Downstream Regulatory Element Antagonist Modulator) ligand (Kd=4.63 uM), inhibits the KV4.3/DREAM current in a concentration-, voltage-, and time-dependent-manner.

IR415 is a novel small molecule inhibitor of HBV virus replication that blocks hepatitis B virus X protein (HBx, Kd=2 nM) mediated RNAi suppression, reverses the inhibitory effect of HBx protein on activity of the Dicer endoribonuclease.

IRAK inhibitor 1 is an interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor.

IRAK inhibitor 2 is interleukin-1 receptor associated kinase inhibitor .

IRAK inhibitor 6 is interleukin-1 receptor associated kinase 4 (IRAK-4) inhibitor .

Irampanel (BIIR 561) is a combined antagonist of AMPA receptors (AMPAR) and voltage-dependent sodium channels.

Irampanel (BIIR 561) is a combined antagonist of AMPA receptors (AMPAR) and voltage-dependent sodium channels.

Irdabisant (CEP-26401) is a potent, selective, orally active histamine H3 receptor antagonist with Ki of 2 nM and 7 nM for human and rat H3Rs, respectivity.

Irdabisant (CEP-26401) is a potent, selective, orally active histamine H3 receptor antagonist with Ki of 2 nM and 7 nM for human and rat H3Rs, respectivity.

IRE1α-IN-3 is a novel, potent IRE1α RNase inhibitor with EC50 of 0.82 uM.

Irinotecan hydrochloride is the hydrochloride salt of a semisynthetic derivative of camptothecin, a cytotoxic, quinoline-based alkaloid extracted from the Asian tree Camptotheca acuminata.

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.

IS-741 (Fuzapladib, IS741) is a synthetic anti-inflammatory agent that shows inhibitory effect on cytosolic phospholipase A2 (cPLA2)..

ISA-2011B is a PIP5Kα inhibitor with promising anticancer effects .

ISA27 is a novel small molecule that blocks p53-MDM2 interaction and induces apoptosis both in vitro and in vivo.

Isatin is an endogenous MAO inhibitor.

Isatoribine is a selective agonist of TLR7

Isavuconazole(BAL-4815; RO-0094815) is the active component of the new azole antifungal agent BAL8557, exhibits MIC(50)s/MIC(90)s ranged from 0.002/0.004 mg/liter for C. albicans to 0.25/0.5 mg/liter for C. glabrata.

Isavuconazonium is a water-soluble prodrug form of the azole antifungal isavuconazole (ISA).

Isepamicin Sulphate is an aminoglycoside antibiotic, which inhibits bacterial protein synthesis by targeting the bacterial 30S ribosomal subunit.

ISO-66 is a novel, highly stable, small-molecule MIF inhibitor that inhibits MIF tautomerase activity with IC50 of 1.4 uM.

ISO-92 is a potent inhibitor of macrophage migration inhibitory factor (MIF) tautomerase activity with IC50 of 0.55 uM..

Isoastragaloside IV is a triterpene oligoglycoside isolated from Astragali Radix.

Isobutyl-deoxynyboquinone (IB-DNQ) is a selective substrate for NAD(P)H:quinone oxidoreductase (NQO1), produces ROS, and induces cytotoxicity in cancer cells in an NQO1-dependent manner.

Isocarboxazid is a non-selective and irreversible inhibitor of monoamine oxidase, with an IC50 of 4.8 μM for rat brain monoamine oxidase in vitro.

Isocryptotanshinone is a potent signal transducer and activator of transcription 3 (STAT3) and protein tyrosine phosphatase 1B PTP1B inhibitor, with an IC50 of 56.1 μM for PTP1B.

Isoginkgetin (Iso-ginkgetin.

Isomangiferin is the major tetracyclic oxindole alkaloid components of Uncaira species, inhibits NMDA receptor with IC50 of 43.2 uM, also blocks calcium channel.

Isomigrastatin (iso-Migrastatin) is an analogue of migrastatin that shows potent antiproliferative effect on tumor cell lines and selectively inhibits translation.

Isonicotinic acid is a metabolite of isoniazid. It is an isomer of nicotinic acid.

Isoquercitrin is an effective antioxidant and an eosinophilic inflammation suppressor.

Isotanshinone I has inhibitory activity against α-glucosidase and formation of AGE, with IC50s of 1.13, 0.432 μM for α-glucosidase and AGE, respectively.

Isotanshinone IIA, an abietane-type diterpene metabolite, could non-competitively inhibit Protein Tyrosine Phosphatase 1B (PTP1B) activity with an IC50 0f 11.4 μM.

Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM.

Isradipine(Dynacirc) is a calcium channel blocker with an IC50 of 34±8 μM.

iST2-1 is a first-in-class, in vivo active ST2 (suppression of tumorigenicity 2) inhibitor with IC50 of 56.14 and 54.62 uM in AlphaLISA and the HEK-Blue IL-33 assay, respectively.

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

Istaroxime(PST2744) is a positive inotropic agent that mediates its action through inhibition of sodium/potassium adenosine triphosphatase (Na+/K+ ATPase).

IT1t dihydrochloride is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

IT1t is a potent CXCR4 antagonist; inhibits CXCL12/CXCR4 interaction with an IC50 of 2.1 nM.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITX-5061 is a scavenger receptor B1 antagonist that promotes high-density lipoprotein (HDL) levels.

ITZ-1 is a client-selective Hsp90 inhibitor that efficiently induces heat shock factor 1 (HSF1) activation, selectively inhibits IL-1β-induced MMP-13 production (IC50=0.51 uM) via inhibition of ERK activation.

IU1-47 is a potent, selective small-molecule inhibitor of USP14 with IC50 of 0.6 uM, shows 10-fold more potent over IU1 and retains specificity for USP14; accelerates the rate of degradation of wild-type tau, the pathological tau mutants P301L and P301S, and the A152T tau variant in primary neuronal cultures, a specific residue in tau, lysine 174, is critical for the IU1-47-mediated tau degradation by the proteasome; stimulates autophagic flux in primary neurons.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

Ivacaftor (VX-770, VX770) is a potent, orally bioavailable CFTR potentiator, increases G551D- and F508del CFTR-mediated Cl- secretion with EC50 of 100 nM.

IWP-O1 is a porcn inhibitor with an EC50 value of 80 pM in a cultured cell reporter assay of Wnt signaling and effectively suppresses the phosphorylation of Dvl2/3 in HeLa cells.

J-113397 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor/ORL1) antagonist with IC50 of 2.3 nM.

J8-C8 is a small-molecule inhibitor of bacterial N-acyl-homoserine lactone synthase (acyl-HSLs) TofI with IC50 of 35 uM for toxoflavin production.

JAK1-IN-31 is a potent and selective JAK1 inhibitor with Ki of 1.9 nM, less potent for JAK3 (Ki=280 nM) and Tyk2 (Ki=12 nM) and no inhibition on hERG and CYP3A4 (IC50>10 uM).

JAK2 inhibitor G5-7 is a small molecule, allosteric JAK2 inhibitor that selectively inhibits JAK2-mediated phosphorylation and activation of EGFR and STAT3 by binding to JAK2.

JAK3i is a selective, covalent JAK3 kinase inhibitor with IC50 of 0.43 nM, shows high selectivity (>3,000-fold) against the closely related kinase domains in JAK1, JAK2, or TYK2, displays 1,300-fold, 600-fold, and 50-fold over EGFR, ITK, and BTK respectiv

JAK3-IN-1 is a potent and selective JAK3 inhibitor with IC50 of 4.8 nM.

JAK-IN-35 is a potent and efficacious dual JAK1/JAK3 inhibitor with IC50 of 0.9/1.9 nM.

Jarin-1 is the first small-molecule inhibitor of JAR1 (IC50=3.8 uM) that inhibits jasmonate responses in Arabidopsis thaliana.

JAS239 is a novel carbocyanine dye that binds and competitively inhibits choline kinase (ChoK) intracellularly, prevents choline phosphorylation and induces cell death in breast cancer cell lines.

JBJ-01-162-04 is a small molecule targeting the flavivirus E protein with broad-spectrum activity, shows activity against DENV in the infectivity assay with IC90 of 0.1 uM.

JBJ-16-111 is a small molecule that inhibits dengue virus (DENV) by binding to its envelope protein E..

JC-171 is a selective NLRP3 inflammasome inhibitor that inhibits LPS/ATP-induced IL-1β release from macrophages with IC50 of 8.45 uM.

JCP251 is a selective small molecule inhibitor of S. aureus serine hydrolase FphB, effectively reduces infectivity in vivo..

JCR 795b is a competitive, small molecule inhibitor of choline kinase (ChoK) with in vitro IC50 of 3.5 uM.

JDTic 2Hcl is a highly selective antagonist for the κ-opioid receptor; without affecting the μ- or δ-opioid receptors.

JF5 (PAR1 inhibitor JF5) is an allosteric inhibitor of PAR1 that binds to helix 8 of the receptor.

JG-231 is an allosteric inhibitor that disrupts the Hsp70-BAG3 interaction (Ki=0.11 uM), inhibits breast cancer cells MCF-7 and MDA-MB-231 with IC50 of 0.12 and 0.25 uM, respectively.

JH-IX-179 is a novel highly potent and selective type I ATP competitive pan-FLT3 inhibitor with IC50 of 4 and 10 nM for FLT3-ITD and D835Y, respectively.

JH-T4 is a potent small molecule SIRT2 inhibitor with IC50 of 0.3 uM (sirtuin deacylation activity), increase intracellular K-Ras4a lysine fatty acylation.

JH-VIII-157-02 is a potent, orally active, CNS-permeable, second-generation inhibitor of ALK G1202R mutant with IC50 of 2 nM, also shows high potency against a variety of other frequently observed mutants (G1269A, S1206Y, F1174L and C1156Y).

JH-VIII-49 is a potent and selective inhibitor of CDK8 with IC50 of 16 nM, also inhibits CDK19 (IC50=8 nM).

JH-XI-10-02 is a CDK8 PROTAC based on the CDK8 inhibitor JH-VIII-49, induces partial degradation of CDK8 in Jurkat cells with IC50 of 159 nM..

JI130 (JI-130) is a specific Hse1 inhibitor that inhibits the cancer-associated transcription factor Hes1 via the PHB2 chaperone, blocks Hes1-mediated transcriptional repression.

JKA3 inhibitor 31 is a highly potent, selective, reversible, covalent JAK3 inhibitor with IC50 of 49 nM, shows no activity against other JAK kinases.

JM6 (KMO inhibitor JM6) is an orally bioavailable small-molecule prodrug of Ro 61-8048, which is an inhibitor of kynurenine 3-monooxygenase (KMO).

JMV 2959 (AEZS-123) is a potent ghrelin receptor (GHS-R1A) antaognist with binding IC50 of 32 nM.

JNc-440 is a small molecule that significantly and specifically strengthens the TRPV4-KCa2.3 interaction in mouse endothelial cells, but does not systemically activate TRPV4 and KCa2.3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 10181457 is a neutral, potent and selective, brain penetrant H3 antagonist with pKi of 8.93, pA2 of 9.22 for hH3.

JNJ 39220675 is potent and selective, brain penetrant H3 antagonist with Ki of 1.4 nM, pA2 of 9.42 for hH3.

JNJ 42153605 is a positive allosteric modulator of the metabotropic glutamate 2 receptor.

JNJ-10198409 is a highly potent, selective PDGFRβ inhibitor with IC50 of 4.2 nM.

JNJ16567083 (EMQMCM) is a potent and selective mGluR1 antagonist that shows neuroprotective effects in some hypoxia-ischemia models.

JNJ-1661010 is a potent and selective FAAH inhibitor with IC50 of 10 nM (rat) and 12 nM (human), exhibits >100-fold selectivity for FAAH-1 when compared to FAAH-2.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-18038683 is a potent, selective 5-HT7 receptor antagonist with pKi of 8.19 and 8.20 for rat and human 5-HT7 in cell-based assays.

JNJ-1A is a novel Dengue virus (DENV) NS4B inhibitor that inhibits DENV-2 sub-genomic replicon at 0.7 μM, in the absence of cytotoxicity.

JNJ-26489112 (JNJ26489112) is a broad-spectrum anticonvulsant that displays activity in rodents against audiogenic, electrically-induced, and chemically-induced seizures.

JNJ-26993135 is a potent, selective leukotriene A4 hydrolase (LTA4H) inhibitor, inhibits both the epoxide hydrolase and aminopeptidase activities of recombinant human LTA4H with IC50 of 10 nM.

JNJ-28307474 is a potent, selective antagonist of the histamine H4 receptor (H4R), inhibits LPS-induced TNF production..

JNJ-28312141 is a potent, orally active CSF-1 receptor (CSF-1R) kinase inhibitor with IC50 of 0.69 nM.

JNJ-28610244 is a potent, selective agonist of histamine H4 receptor (H4R)..

JNJ303 is a potent, specific delayed rectifier potassium current I(Ks) blocker with IC50 of 64 nM, shows no effects on other cardiac channels (IC50=3.3, >10, 11.1 and 12.6 uM for Na, ICa, Ito and IKr currents).

JNJ-37822681 is a potent, specific and fast-dissociating dopamine D2 antagonist with Ki of 158 nM.

JNJ-38158471(KDR) is a well tolerated, orally available, highly selective VEGFR-2 inhibitor with IC50=40nM. It also inhibits closely related tyrosine kinases, Ret (180nM) and Kit (500nM). It has no significant activity (>1 microM) against VEGFR-1 and VEGF

JNJ-38877618 (OMO-1) is a novel potent, highly selective, orally bioavailable c-Met tyrosine kinase inhibitor with Kd of 1.2, 2.1 and 21 nM for WT, M1250T and Y1235D mutants MET, respectively.

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-38893777 is a potent and selective transient receptor potential vanilloid 1 (TRPV1) channel antagonist for treatment of ociceptive and neuropathic pain..

JNJ-39393406 is a potent, selective positive allosteric α7 nAChR modulator, potentiates a 100 μM choline-induced rise in intracellular calcium mediated by human α7 channels expressed in GH4C1 cells with EC50 of 660 nM.

JNJ-39729209 is a potent, selective TRPV1 antagonist with binding pKi of 7.8 and 7.9 for human and rat TRPV1, respectively.

JNJ-39933673 hemihydrate is a potent, selective SGLT2 inhibitor..

JNJ-39933673 is a potent, selective SGLT2 inhibitor..

JNJ-40279486 is a potent, selective histamine H4 receptor antagonist with Ki of 9.4 nM (hH4), demonstrates acceptable pharmacokinetic profile and efficacy in mouse model of inflammation..

JNJ-40413269 is a potent, selective, blood brain barrier (BBB) penetrant FAAH inhibitor with IC50 of 5.3 and 6.3 nM for hFAAH and rFAAH, respectively.

JNJ-42314415(JNJ42314415) is a potent, selective, centrally active phosphodiesterase 10A (PDE10A) inhibitor with Ki of 35 nM for human recombinant PDE10A.

JNJ-42905343 is a potent, selective, orally active prolyl hydroxylase (PHD) inhibitor with pKi of 8.07, 7.48 and 7.27 for PHD1, PHD2 and PHD3 respectively.

JNJ-47965567 is a potent, selective, centrally permeable P2X7 receptor antagonist with pKi of 7.9 and 8.7 for human and rat P2X7, respectively.

JNJ-49095397 (RV-568) is a specific narrow-spectrum kinase inhibitor that inhibits a selected set of kinases involved in COPD inflammation with IC50 of 5, 40 and 52 nM for p38α, p38γ and HCK, respectively.

JNJ-4929821 is a potent, reversible methionine aminopeptidase-2 (MetAP-2) inhibitor with IC50 of 8 nM..

JNJ-5207852 is a selective and potent histamine H3 receptor (H3R) antagonist, with pKis of 8.9, 9.24 for rat and human H3R, respectively.

JNJ-5234801 is an atypical anxiolytic targeting 5-HT2 receptor, has demonstrated oral activity in animal models of anxiety..

JNJ525 is a small molecule inhibitor of TNFα that prevents the formation of TNFα complexes with TNFR1 and TNFR2 with IC50 of 1.2 uM and 1.1 uM in the TR-FRET assay, respectively..

JNJ-53718678 (JNJ53718678, JNJ-678) is a potent (Kd=7.4 nM), small-molecule inhibitor of the F-glycoprotein-mediated complex membrane fusion process of the RSV.

JNJ-54175446 is a potent and selective brain penetrant P2X7 receptor antagonist, with pIC50s of 8.46 and 8.81 for hP2X7 receptor and rP2X7 receptor, respectively.

JNJ-55308942 is a novel highly potent P2X7 antagonist with Ki of 1.0 and 6.5 nM for rat and human hP2X7, demonstrates significant activity against a panel of related P2X receptors (P2X1, P2X2, P2X3, P2X2/3, and P2X4.

JNJ-55511118 (JNJ55511118) is a selective, orally available AMPA receptor containing TARP-γ8 negative modulator with Ki of 26 nM, displays no significant activity against other TARP-less AMPARs and AMPARs coexpressed with other TARPs or CNIH2.

JPC-3210 is a potent antimalarial agent with IC50 of 2.5-19 nM, remains activity against multidrug-resistant Plasmodium falciparum lines with little cytotoxicity in mammalian cell lines.

JPH203 (KYT-0353) is a potent, selective L-type amino acid transporter 1 (LAT1, SLC7A5) inhibitor with IC50 of 60 nM (leucine uptake inhibition), but not LAT2.

JPI-289 (JPI289) is a novel potent, water soluble PARP-1 inhibitor with IC50 of 18.5 nM, inhibits cellular PAR formation with IC50 of 10.7 nM.

JQ1-VHL-PROTAC is a novel PROTAC synthesis..

JQ-35, (S)- is an inhibitor of the Bromodomain and Extra-Terminal (BET) family bromodomain-containing proteins with potential antineoplastic activity.

JSF-4088 (JSF4088) is a novel antitubercular agent with potent in vitro antitubercular potency (MIC=19 nM), with no significant Vero cell cytotoxicity (CC50 >120 uM)..

JSH-150 (JSH150) is a potent, highly selective inhibitor of CDK9 kinase with IC50 of 1 nM in the biochemical assays, displays 300-10000-fold selectivity over other CDK kinase family members (CDK7 IC50=1.72 uM).

JTE-952 (JTE952) is a potent, selective colony stimulating factor-1 receptor (CSF1R) type II inhibitor with IC50 of 14 nM, shows cellular activity in BMMCs IL-6 secretion assays with IC50 of 20 nM.

JTP-117968 is a novel orally available, selective glucocorticoid receptor modulator (SGRM) with IC50 of 6.8 nM.

JTT-551 (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR.

JTT-551 sodium (JTT551, JTT 551) is a novel potent, selective inhibitor of protein tyrosine phosphatase 1B (PTP1B) with Ki of 0.22 uM, displays >45-fold and >136-fold selectivity over TCPTP, CD45 and LAR.

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTT-553 is a novel potent, selective DGAT-1 inhibitor with IC50 of 2.38 nM, shows no inhibitory activity for human DGAT2 and ACA T1 (IC50>10 uM).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

JTV-519 (K201) is a Ca2+-dependent blocker of SERCA and a partial agonist of ryanodine receptors (RyRs).

Juniferdin is a small molecule, potent Protein disulfide isomerase (PDI) inhibitor with IC50 of 156 nM, inhibits PDI-mediated reduction of HIV-1 envelope glycoprotein gp120.

JVW-1034 is a selective small molecule modulator of σ2R/Tmem97 with Ki of 23 nM, 10-fold weaker affinity for σ1R (Ki=248 nM).

JW 642 (JW642) is a potent, selective monoacylglycerol lipase (MAGL) inhibitor with IC50 of 7.6, 14 and 3.7 nM for mouse, rat and human MAGL, respectively.

JW-7-25-1 is a potent MELK inhibitor with biochemical IC50 of 5.0 nM, also inhibits PIK3CA, mTOR, GSK3A and CDK7 with CI50 of 5-60 nM.

JYL-1421 (SC-0030) is a potent, competitive TRPV1 receptor antagonist with Ki of 53.5 nM, antagonizes capsaicin-induced calcium uptake with EC50 of 9.2 nM.